This is the authors' abstract. We don't add key points for this paper.
Letter to the Editor Inherited metabolic diseases (IMDs) are a group of heterogenous genetic disorders resulting in substrate accumulation, energy deficiency or complex molecular defects due to the failure of specific molecules to act as enzymes, cofactors, transporters, or receptors in specific metabolic pathways.1, 2 The pathophysiological changes seen in IMDs are on a cellular or sub-cellular level and therefore affect different systems, not just affecting a single organ. The majority of IMDs exhibit a recessive mode of inheritance.3 Despite each disorder being considered rare and affecting only a small cohort of patients, the combined occurrence of various rare diseases leads to a noteworthy prevalence of 1 in 784 live births.4, 5 The number of adult patients with an IMD is increasing due to newborn screening and improved treatments in childhood, adolescence and adulthood6 leading to increased survival rates. Endocrine disorders are commonly encountered in IMDs but are underrecognized.4 Endocrine disorders may present following diagnosis in childhood or in adults where there is multi-system or multigland involvement, before any metabolic diagnosis being made. Endocrinopathies may be secondary to treatment (e.g., due to chemotherapy used for hematopoietic stem cell therapy [HSCT] to treat IMDs). The most common endocrinopathies are type 1 and type 2 diabetes mellitus, hypogonadism, adrenal insufficiency, and thyroid dysfunction.7 Given the physical and psychological burden of these conditions and the advent of new treatments for IMDs that may affect the endocrine system, it is important that clinicians are aware of the potential endocrine manifestations of IMDs and how best to screen for/manage these challenges. In our hospital, which is a tertiary referral centre for endocrinology and IMD, patients are identified in both dedicated metabolic and endocrinology clinics. Once identified they are reviewed in a joint supra-regional endocrinology/metabolic clinic by an adult IMD physician as well as an endocrinologist with input from specialist dietitians, physiotherapy and the clinical biochemistry laboratory. Where necessary, other are involved in decisions about ongoing patient management in the short and the longer term. To characterise the nature of the patient presentations in the joint endocrinology/metabolic clinic, the clinical and biochemical details have been tabulated in Table 1. Data were categorised by metabolic disorder and further grouped by type of endocrinopathy seen. Where a mechanism for the IMD-associated endocrinopathy is known, this is included in the table as are relevant biochemical findings and the implemented management plans. We have confined our description to patients being seen as adults (≥16 years old) although most of them were diagnosed with an IMD in childhood and were previously under the care of a paediatric team. ↑ LH/FSH ↓Oestradiol ↓ Anti-mullerian hormone HRT Referral to fertility clinic Adrenal insufficiency (n = 4) Hypogonadism (n = 1), fluctuation of blood pressure (n = 1) ↓Cortisol ↓Glucose ↓DHEA Mucopolysaccharidosis type I Hurler (MPS IH) post hematopoietic stem cell transplantation (HSCT) (IDUA) ↓ Testosterone (males) ↑ LH/FSH ↑ TSH ↓FT4 ↑TPO Testosterone/HRT Bone density monitoring Steroids + levothyroxine for hypothyroidism postacute thyroiditis ↑ LH/FSH ↑ FAI ↑ Glucose ↓Oestradiol ↓ Anti-mullerian hormone Pelvic ultrasound scan Carnitine palmitoyltransferase II (CPT II) deficiency (CPT2) ↑FT4 TSH normal Glycogen storage disorders (GSDs): GSD IX*, GSD Ia (post CLK transplant) and GSD Ib (PHAK1, G6PC, G6PT1) Subfertility (n = 2), Oligo/amenorrhoea (n = 2), hypogonadism and low libido (n = 2), PCOS (n = 1), thyroid nodule (n = 1), osteopenia (n = 1) GSD Ia/Ib: Altered glucose metabolism resulting in hyperinsulinemia and subsequent hyperandrogenism and gonadotrophin excess, oestrogen deficiency resulting in low bone density GSD IX: Antiepileptic use affected protein binding, which resulted in low free testosterone ↑ LH/FSH ↑ FAI ↑/↓Glucose ↓Oestradiol ↓ Anti-mullerian hormone Normal ovarian ultrasound Norethisterone prescribed, monitoring of bone density, dexamethasone suppression test/CGM for recurrent hypoglycaemia Endo-gynaecology clinic, Psycho-sexual counselling USS for PCOS symptoms– normal, Sperm analysis normal ↓ TSH ↑ FT4 ↑ TPO ↑LH/FSH ↑ Prolactin ↑ Testosterone Methylenetetra-hydrofolatereductase (MTHFR) deficiency (MTHFR) ↓ TSH ↑ FT4 Plasma metanephrines, urine catecholamines, ACTH, cortisol and dexamethasone suppression test ↑HbA1C ↑ Glucose ↑/↓ LH/FSH ↓ Oestradiol FAI ↑↑ Androstenedione ↑ Prolactin ↑↑ HbA1c ↑ Serum cortisol ↑ LH ↓ FSH = , TSH = ↑Urine-free cortisol excretion ↓ Testosterone (males) ↑ LH/FSH Glucose ↓ TSH↑ FT4↓ Ketotic hypoglycaemia, hypothyroidism Pituitary adenoma, (n = 1) Over the 7 years up to end of 2023, 46 patients were seen in our joint endocrinology/metabolic. 61.0% of the attendees were women and 67.5% of patients had a solitary endocrine disorder with (sub)infertility problems being the most frequent reason for attendance. 28.2% had two endocrine conditions and 4.4% had at least three endocrine complications. The most prevalent IMDs related to endocrine complications included classical galactosemia, X-linked adrenoleukodystrophy, mucopolysacharidosis type I Hurler (MPS IH) post haemopoietic cell transplantation (HSCT), and mitochondrial disorders (described in detail in Table 1). The most common endocrine complications we found in our cohort were diabetes mellitus (DM) (type 1 and type 2), thyroid dysfunction, gonadal dysfunction, polycystic ovarian syndrome (PCOS) and adrenal insufficiency. A proportion of patients in our cohort developed endocrine complications directly related to the metabolic pathways (classical galactosemia, glycogen storage diseases; GSDs). In some other cases, the association between an IMD and the hormonal abnormality is either incidental or probable or may not have been described before (hirsutism in Refsum's or hypogonadism and high prolactin in Lesch–Nyhan syndrome). In the case of recessive conditions, in a large proportion of cases there was a consanguinity in family. In this cohort, 41.3% (19/46) of women required either hormonal replacement therapy (HRT; tablets/patches), oral contraceptive pill or progesterone only pill. A component of the role of an MDT clinic is to discuss preconception readiness among women with IMD, including optimisation of metabolic care, medication management, and carrier screening. HRT/contraception may mitigate clinical manifestations of an IMD such as aggressiveness and/or seizures during catamenial metabolic crisis in patients with urea cycle disorders.8 Discussion about reproductive health may involve care coordination with General Practitioners and other specialties involved in their care. These healthcare providers may need education about risks of using the HRT in IMDs. Every appointment is a joint clinic review by the endocrinologist and IMD specialist. The clinic is attended by a metabolic multidisciplinary team including a dietician, physiotherapist or a nurse. The time of the consultation is 30 min for a structured and endocrinology focused joint review. In many cases, the choice of treatment is limited by various factors, which must be taken into account to improve therapeutic adherence. Intellectual disability, complications derived from the disorder itself, the patient's social support, and the way the drugs are administered are some of the factors to consider. Learning disability is a feature of several IMDs; in our cohort; 26% had mild/moderate type of learning disability. For men and women with learning disability, supported decision-making occurs with a trusted metabolic clinician and multidisciplinary team nurse, who act in the best interest of the person. Hence any intervention and benefits of therapy are often discussed as part of best interest meeting and the intervention considered only if it is to improve patient's well-being, and to treat the reversible and life-threatening abnormality. We accept that a limitation of our report is that numbers are relatively small, with marked heterogeneity in terms of conditions included. As a result the description of endocrinopathy for any of the given inherited conditions is limited to very small numbers. In conclusion, endocrine disorders are long-term complications of IMDs and they require screening for and management by a specialist endocrinologist. Signs and symptoms of common hormonal problems may be wrongly attributed to the underlying IMD, if not diagnosed before. It is important for clinicians to have a high index of suspicion for an IMD if a patient presents with atypical or multi-glandular endocrinopathies. Advice on hormone replacement treatment choice should consider its effects on metabolism, efficacy, drug-drug interactions, co-morbidities, side effects and patient's preference. Adrian H, Heald, John Bassett, and Nuria Puente-Ruiz wrote the manuscript with collation of the data for Table 1 by NPP and Karolina M. Stepien. Peter Clayton and Karolina M. Stepien provided expert overview. All authors approved the final version of the manuscript. No external funding was received for the work reported here. All authors declare no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work. The data that supports this report are patient-specific and only available in summary form.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Heald et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: